Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of Safety, Tolerability, and Efficacy of zagotenemab in Early Symptomatic Alzheimer's Disease
jRCT2080223944Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing zagotenemab IV with Placebo IV (2 arms). Started Jun 2018; status: completed.
02
Drugs
zagotenemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2080223944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223944.